Hapten-carrier conjugates for treating and preventing nicotine addiction
Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.
1. A method of preventing nicotine addiction in a patient in need of such prevention, comprising administering a therapeutically effective amount of a hapten of formula II:
wherein
n is 1 to 12;
Z is NH 2 , COOH, CHO or SH, and
—(CH 2 ) n —Z can be bonded to the 3′, 4′ or 5′ position, wherein the Z moiety is bound to a carrier protein, directly or via a linker.
2. A method of treating nicotine addiction in a patient in need of such treatment, comprising administering a therapeutically effective amount of a hapten of formula II:
wherein
n is 1 to 12;
Z is NH 2 , COOH, CHO or SH, and
—(CH 2 ) n —Z can be bonded to the 3′, 4′ or 5′ position, wherein the Z moiety is bound to a carrier protein, directly or via a linker.
3. The method according to claim 1 or 2 , wherein the linker is a succinyl moiety.
4. The method according to claim 1 or 2 , wherein the carrier protein comprises a T-cell epitope.
5. The method according to claim 4 , wherein the T-cell epitope is capable of stimulating the T cells of the patient, whereby B cells are induced to produce antibodies against the hapten carrier conjugate.